

Comparison of several biomarkers (MMP-2, MMP-9, the MMP-9 inhibitor TIMP-1, CTX-II, calprotectin, and COMP) in the synovial fluid and serum of patients with and without septic arthritis

Marion Couderc, Caroline Peyrode, Bruno Pereira, Elisabeth Miot-Noirault, Sylvain Mathieu, Martin Soubrier, Jean-Jacques Dubost

▶ To cite this version:

Marion Couderc, Caroline Peyrode, Bruno Pereira, Elisabeth Miot-Noirault, Sylvain Mathieu, et al.. Comparison of several biomarkers (MMP-2, MMP-9, the MMP-9 inhibitor TIMP-1, CTX-II, calprotectin, and COMP) in the synovial fluid and serum of patients with and without septic arthritis. Joint Bone Spine, 2018, 10.1016/j.jbspin.2018.04.008. hal-01925157

HAL Id: hal-01925157

https://hal.science/hal-01925157

Submitted on 27 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Comparison of several biomarkers (MMP-2, MMP-9, the MMP-9 inhibitor TIMP-1, CTX-II, calprotectin, and

COMP) in the synovial fluid and serum of patients with and without septic arthritis

Marion Couderc^{1,2}, Caroline Peyrode², Bruno Pereira³, Elisabeth Miot-Noirault², Sylvain Mathieu¹, Martin

Soubrier¹, Jean-Jacques Dubost¹.

¹ Rheumatology department, Clermont-Ferrand University Hospital, France

² UMR 1240 Inserm/UCA, IMOST, Clermont-Ferrand, France

³ Biostatistics unit, DRCI, Clermont-Ferrand University Hospital, France

Corresponding author:

Dr. Marion Couderc

Rheumatology department

Clermont-Ferrand University Hospital

Place Henri Dunant,

63000 Clermont-Ferrand, France

Email: mcouderc@chu-clermontferrand.fr

Word count: 470

Disclosure statement: The authors declare that they have no financial or any other conflicts of interest in

relation to this manuscript.

It is critical to diagnosis septic arthritis (SA) in a timely fashion in order to reduce the risk of irreversible cartilage damage, which has important functional sequelae [1,2]. However, direct Gram stain of synovial fluid is positive in only 25% to 50% of SA cases, and the bacteriological results remain negative in approximately 20% of SA cases [3]. Therefore, readily available and specific biomarkers are needed to help clinicians to decide for hospitalization and antibiotic treatment. This study assessed whether the following serum and synovial biomarkers could distinguish between patients with SA versus non-SA: metalloproteinase MMP-2, MMP-9, tissue inhibitor of MMP (TIMP-1), cartilage oligomeric matrix protein (COMP), C-terminal telopeptide of type II collagen (CTX-II), and calprotectin (CALP).

Serum samples and aspirated synovial fluid samples were prospectively collected from 21 patients with SA. SA was defined as the identification of microorganisms from synovial fluid or blood cultures: *Staphylococcus aureus*, n=13; *Streptococcus*, n=4; *Enterobacteria*, n=3; and coagulase-negative *Staphylococcus*, n=1. We also collected samples from 18 patients with a suspicion of SA who had acutely swollen joints due to other causes: chondrocalcinosis, n=9; gout, n=2; rheumatoid arthritis, n=2; spondyloarthritis, n=1; osteoarthritis, n=3; and hemarthrosis, n=1. TIMP-1, MMP-2, MMP-9, CTX-II, CALP, and COMP levels were measured in synovial fluid and serum using commercial enzyme-linked immunosorbent assay (ELISA) kits and compared between the groups.

The characteristics of the study population are shown in Table 1. Univariate analysis showed that the following were significantly higher in the SA group versus the non-SA group (Table 2): serum TIMP-1 (p<0.01), synovial MMP-9 (p<0.01); serum (p<0.05) and synovial CTX-II (p<0.01); and serum (p<0.05) and synovial CALP (p<0.05). The AUCs for diagnosing SA based on synovial MMP-9, serum TIMP-1, synovial CTX-II, and serum and synovial CALP were 0.84, 0.79, 0.81, 0.7, and 0.72, respectively. When serum TIMP-1 and synovial CTX-II were combined and thresholds of 286.5ng/mL and 873ng/mL were used, respectively, the sensitivity was 75% and the specificity was 94% for diagnosing SA. This combination correctly classified patients in 86% of cases. Synovial MMP-9 substantially correlated with C-reactive protein (r=0.61), whole blood white blood cell count [WBC] (r=0.46), synovial WBC (r=0.66) and the polymorphonuclear cell percentage (r=0.51) in synovial fluid. Serum TIMP-1 and synovial CTX-II did not correlate with each other (r=0.1) or with CRP (r=0.4 and r=0.25, respectively) or synovial WBC (r=-0.04 and r=0.27, respectively).

Table 1: Clinical characteristics and laboratory data of the study population

	_			
		SA group	Non-SA group	p-value
		n = 21	n = 18	
Age , years, mean <u>+</u> SD		64.5 ± 21.1	64.8 ± 12.6	0.96
Male gender, n (%)		12 (57.1)	8 (44.4)	0.43
Diabetes, n (%)		5 (23.8)	2 (11.1)	0.42
Joint affected	Knee, n (%)	14 (66.7)	15 (83.3)	0.24
	Shoulder, n (%)	4 (19)	2 (11.1)	
	Hip, n (%)	3 (14.3)	0 (0)	
	Elbow, n (%)	0 (0)	1 (5.6)	
Max. temperature, °C, mean <u>+</u> SD		38.3 ± 0.7	38.1 ± 0.7	0.38
Chills, n (%)		7/18 (38.9)	4/18 (22.2)	0.28
Presence of an entry site for infection, n (%)		15/20 (75)	8/18 (44)	0.054
Serum: WBC count, /mm³, median		10 770 [8250-13 260]	8230 [4900-11 400]	0.03*
CRP, mg/L, median [Q1-Q3]		209 [122-256]	90 [35-184]	0.06
Radiological signs of SA, n (%)		7/18 (38.9)	1/17 (5.9)	0.04
Synovial fluid:				
Turbid, n (%)		13/19 (68.4)	2/17 (11.8)	0.001*
WBC count > 50 000/mm ³ , n (%)		7/16 (43.7)	3/18 (16.7)	0.09
PMN, %, median [Q1-Q3]		90 [89-93]	89 [84-90]	0.17

Values are expressed as mean \pm standard deviation (SD) or median [Q1-Q3] for continuous variables and n (%) for categorical variables. * < 0.05

SA: septic arthritis, CRP: C-reactive protein, WBC: white blood cell, PMN: polymorphonuclear cell

Table 2: Measurement of the biomarkers according to diagnosis (septic or non-septic arthritis)

Marker level	Septic arthritis (n=21)	Non-septic arthritis (n=18)	<u>p-value</u>
MMP-2 serum, mean ± SD, ng/mL	90 <u>+</u> 35.6	77.1 <u>+</u> 26.5	0.2
MMP-2 synovial fluid, mean ± SD, ng/mL	248.5 <u>+</u> 131	241.8 <u>+</u> 109.4	0.7
MMP-9 serum, mean ± SD, ng/mL	2856 <u>+</u> 1997	2190 <u>+</u> 1920	0.2
MMP-9 synovial fluid, mean <u>+</u> SD, μg/L	49.6 <u>+</u> 26.3	20.7 <u>+</u> 16.5	0.002*
TIMP-1 serum, mean <u>+</u> SD, ng/mL	320.6 <u>+</u> 169	170.8 <u>+</u> 69.2	0.003*
TIMP-1 synovial fluid, mean <u>+</u> SD, ng/mL	947 <u>+</u> 315	948.1 <u>+</u> 377.1	0.7
CTX-II serum, mean <u>+</u> SD, ng/mL	1036.9 <u>+</u> 549.2	653.5 <u>+</u> 268	0.03*
CTX-II synovial fluid, mean ± SD, ng/mL	1069.9 <u>+</u> 540.3	673.5 <u>+</u> 335.5	0.004*
COMP serum, mean <u>+</u> SD, ng/mL	304.4 <u>+</u> 216.1	271.4 <u>+</u> 157.3	0.8
COMP synovial fluid, mean <u>+</u> SD, ng/mL	4210 <u>+</u> 3523	6098 <u>+</u> 4161	0.2
CALP serum, mean + SD, mg/mL	2.5 <u>+</u> 1.4	1.6 <u>+</u> 1	0.04*
CALP synovial fluid, mean <u>+</u> SD, μg/mL	1270.9 <u>+</u> 605.3	798.1 <u>+</u> 604.8	0.03*

To our knowledge, this is the first study to assess the performance of numerous potentially useful markers in synovial fluid and serum samples of patients with suspected SA. Synovial CTX-II is especially interesting because it appears to add new information regarding cartilage degradation, along with inflammatory host response biomarkers like synovial WBC or CRP.

This preliminary study demonstrates that two biomarkers, serum TIMP-1 and synovial CTX-II, merit further assessment in terms of their diagnostic and prognostic value in a larger cohort of patients with suspected SA.

^{*:} p-value < 0.05, Mean + SD: mean and standard deviation, AUC: area under the curve, CI: confidence interval, MMP: metalloproteinase, TIMP: metalloproteinase inhibitor, CTX: C-terminal telopeptide of collagen, COMP: cartilage oligomeric matrix protein.

References

- [1] Dubost JJ, Soubrier M, Sauvezie B. Pyogenic arthritis in adults. Jt Bone Spine Rev Rhum 2000;67:11–21.
- [2] Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA 2007;297:1478–88.
- [3] Eberst-Ledoux J, Tournadre A, Mathieu S, Mrozek N, Soubrier M, Dubost J-J. Septic arthritis with negative bacteriological findings in adult native joints: a retrospective study of 74 cases. Jt Bone Spine Rev Rhum 2012;79:156–9.